MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
PTC Therapeutics Accounts Receivables 2011-2026 | PTCT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PTC Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 182 M | 159 M | 161 M | 156 M | 110 M | 69.9 M | 55.5 M | 67.9 M | 40.4 M | 24.9 M | 11.1 M | 4.44 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 182 M | 4.44 M | 86.8 M |
Quarterly Accounts Receivables PTC Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 203 M | 196 M | 210 M | 159 M | 200 M | 187 M | 198 M | 161 M | 166 M | 178 M | 202 M | 156 M | 124 M | - | 141 M | 110 M | 96.6 M | 78.8 M | 94.1 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 67.9 M | 67.9 M | 67.9 M | 67.9 M | 40.4 M | 40.4 M | 40.4 M | 40.4 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 4.44 M | 4.44 M | 4.44 M | 4.44 M | 958 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 210 M | 958 K | 84.2 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
98.7 M | $ 22.56 | 2.13 % | $ 3.74 B | USA |
 |
Akebia Therapeutics
AKBA
|
47 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Alnylam Pharmaceuticals
ALNY
|
778 M | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
CymaBay Therapeutics
CBAY
|
277 K | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Avid Bioservices
CDMO
|
16.6 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
1.69 M | - | - | $ 1.41 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
218 K | - | - | $ 401 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.49 | 9.56 % | $ 397 M |  Britain |
 |
CTI BioPharma Corp.
CTIC
|
15.4 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
32 M | - | - | $ 2.18 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
45.3 M | - | - | $ 2.02 B | USA |